TrovaGene, Inc. Company Profile
With its headquarters and product development in San Diego, California, TrovaGene has focused on development of tests using its patented transrenal nucleic acid technology. Transrenal DNA (Tr-DNA) and RNA (Tr-RNA) are short nucleic acid fragments from normal cell death that cross the kidney barrier and can be detected in urine. Safe and simple urine collection and analysis can replace biopsy or blood sampling and has a broad range of applications, including tumor detection and monitoring, infectious disease detection, prenatal testing, tissue transplantation, genetic testing for forensic identity determination, and testing associated with drug development. The TrovaGene molecular diagnostics assays will provide information that will enable physicians to provide personalized medical care for their patients.
News Articles
Trovagene Launches Easier Test for HPV Infection
TRENTON, N.J. (AP) — Shares of Trovagene Inc. jumped Wednesday after the maker of molecular disease-detecting tests launched its new urine-based test for a common, sexually transmitted virus that ca...
Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
SAN DIEGO, Aug. 15, 2012 /- Trovagene, Inc. (Nasdaq: TROV), a developer of transrenal molecular diagnostics, today reported its financial results for the three and six months ended June 30, 2012...
[Novartis]' [Genoptix] gets rights to NPM1 from [Trovagene]
Diagnostic firm [Trovagene Inc.] has licensed [Novartis AG]’s [Genoptix Inc.] (cancer tests) a nonexclusive global license to use nucleophosmin protein (NPM1) in its research and clinical testing se...
Trovagene licenses marker to Duke University
Duke University and Duke University Health Systems obtained nonexclusive rights to use Trovagene's nucleophosmin protein for -More-
Will The Latest PerkinElmer Agreement Help TrovaGene Tap Into A $22 Billion Market?
ByFree Bird: TrovaGene (TROV) is a small and undervalued biotech company that has recently had its core technology validated by PerkinElmer (PKI). On April 25, 2013, Trovagene, Inc. entered into a Re...
Trovagene 'Ups The Ante' With PerkinElmer Collaboration
By VFC: The imminent expectation of multiple product launches during the course of the coming year and the further development of a pipeline full of urine-based diagnostics designed to detect various...
Trovagene Added to Russell Microcap Index
Russell Investments has added Trovagene, a developer of transrenal molecular diagnostics, to the Russell Microcap Index.
Trovagene Grants License For NPM1 Marker To Quest Diagnostics For AML
WASHINGTON (dpa-AFX) - Trovagene, Inc. (TROV) said it has granted Quest Diagnostics Inc. (DGX) a non-exclusive license to incorporate nucleophosmin protein, or NPM1, into research and clinical tes...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
With its headquarters and product development in San Diego, California, TrovaGene has focused on development of tests using its patented transrenal nucleic acid technology. Transr...
More Information about "TrovaGene, Inc." on BioPortfolio
We have published hundreds of TrovaGene, Inc. news stories on BioPortfolio along with dozens of TrovaGene, Inc. Clinical Trials and PubMed Articles about TrovaGene, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of TrovaGene, Inc. Companies in our database. You can also find out about relevant TrovaGene, Inc. Drugs and Medications on this site too.
